CD44 and neoplasm: si-hVDAC1 tumor treatment markedly decreased the expression of CSCs markers, such as CD133, SOX2, KLF4, Nestin, and CD44, as evaluated by quantitative immunoblotting (Figure 2A–D) and qRT-PCR (Figure 2E,F).